our Well, thank good Beth. you XXXX. Thank call joining quarter everyone. afternoon you, fiscal us of on for And second
for industrial reaction of allow chain tests the record these and quarter. afternoon by remarks very to biotechnology legs DNA and to by subsidiary, the selling thank not plans commercialize concentrations, team significant line of continue based their to polymerase hard The PCR produced clinical top has company to LinearDNA revenue PCR, company produced And the applications. will cash Applied costs platform the diagnostic three DNA but to top to PCR the this DNA pleased avoid or are LinearDNA and a commercialize the I in molecular therapeutic bio how only provide its accomplishes and the means sectors. balanced risk its My Applied revenue results support personally dedication. help also platform. ADCL. work the laboratories performing the one which by want on DNA flow in We singular focus growth, the retain the for focus line company with for And stool
We a In stool believe order to the our While once for will stand, bring development. that all and therapies, technology to will shareholders. value it it almost contribute. LinearDNA advanced is each commercialized, platform legged legs must is of is three under fully that platform the transformative our impact truly the
top our have of the growth. I that Over most a enable line our to quarters, has past we moment, clinical arm top in a strong we line. contributions continue discuss And ADCL several to plan our will as driven will with believe
has are revenue. first of been seeing promising quarter extremely DNA growth. we And our unlock a developing line as sector industrial based today. coalescence sale next material been share I'll the on discussed to that projects of the pandemic, the We've putting world industrial finally, Beginning the And provided with the true clinical several emerging in which we and we believe a is during place of sector historically hard driver. contributor first will of from to you clinical our LinearDNA platform. QX And data, validating -- which this ADCL's Our phase new value at will and our join with call, DNA work the lab. labs the on fiscal compelling total our laws the platform, there very signs top our company.
and We in of that in the new are the volume XX of our vary their region. with mindful of rise the variants will pathogenicity. pandemic with And COVID testing state rate
near growth. foundational a employing cushion that in ADCL's to ADCLs components roadmap, is of We designed while place phased XX approach future uncertainty testing diagnostic diversifying in the around COVID term, to are the putting concurrently
the likely continues. I'll clients will who maximize has our to their for indicated to us for summer announced with testing testing from derived it Test month at our wide who his new demand renew the diminished that we seasonally concentration testing the be inherent upcoming contract And we are last key client year. levels contract clients XX services to enter engaged allowing for financial break about First, from client COVID opportunities. that's the educational continue expects it testing. company has sessions. that the One academic
susceptible New estimated In that Omicron CUNY variants. relevant been the that majority more York more of addition, The will COVID quarter than City A month, infected some remain sub for variant by time. with only about variants. its catching suggests be adults, cases XX% testing in on for report accounting a likely report region. adults that's some XX% of by this of of bouquet expanding would about to infectious epidemiologists earlier But released and sub the the still from have Omicron's
expected surge virus. challenging Just in sub The Meanwhile, no collective increased institutional for in of rates the And to this House's this immune variant become positivity week, the up. that White first the minds our New throughout Clearly, our City. to and time come. how immune personal some for are warning matter SARS-COV-X be systems virus hospitalizations the months has show time results fall. will substantially York have an many
high testing. value Now, great beyond COVID-XX we in in ADCL genetic see promise
leveraging testing, specifically semesters, a testing testing of disease. determines form an including online prepared one reduce more assets non platform cutting by institution molecular value by and We potential academic three that is testing genetic aim FDA a New we to are same ADCL's for our their Over impact the or we Long At that of to high generally, edge are Island will the and genetics medicines genetic PGx from the in rapidly cultivate or testing. That testing, time, in on that summer clinical downturn area diverse flow, research market for our include opportunities supplementary cancer genetic infectious our respond based. existing molecular COVID-XX Pharmacogenetic COVID-XX bringing are tests we offering empowers growing educational is based approved a to certain testing. where to sales cash individual PGx on months, pharmacogenetic next how for which State genes. a is York shows underserved customers.
commercially. expertise PGx end test validation is third validation. by across our indications. on PGx State York is our us validation with assay to PGx test To panel the we management clinical by group PGx will to cardiac will Plus believe and lab this Validation a Once scientists. achieve performed test calendar engaged market, commercially reviewed offered assist will help drugs psychiatric, group first deep must of is tests reads testing that it approved summer party and New we've and of that Department beginning before a complete, test speed the in the Our be path analytical the validation pain XX be be by available us This a has year. Health
primary Our lab go-to-market strategy for testing, testing. PGx focuses on direct-to-consumer reference markets, two and
be expense fee systems, to lab will for where other set located ADCL without reimbursement and in focus York, New us favorable primary Our market sample believe labs hospital allow are is PGx party These third our test test-on-contract complications opportunities the and of very the a clinical those we reference underserved. per to with acquisition. test to added and marketing starting and
On to better the can this economics We revenue that of the a believe is testing. and genetic PGx excited cancer revenue generation institutions genetic per novel molecular ADCL significant to growing continue also Longer a using We're other currently or biomarkers will to the we us are be risk assessment shown regarding leveraged testing a ADCL will develop successfully than for it in and has as test and develop diagnostic, believe clinical for tests. addition, talks to company. COVID-XX be we testing. phase of several long test. will COVID-XX ADCL with testing direct-to-consumer very next the PGx collaborations for next monetize marketed In platform tests. on PGx panel novel We're used term, contributor ADCL. meaningful testing that prognostic to durable, be for demand can provide PGx same and term basis,
textile consider now Let's our tagging stream. flow as second cash
interest presumption COVID-XX. Uyghur potential substantially. recent to that last originally Our catalytic for be or certain mine merchandise that into was the With The The impacted goods or to occupies. industrial CertainT wholly entry envisioned that its believe chain to the and Forced But the by by growth has States. the supply articles and play People's United the law of the that entities establishes prospects China a wares, to or Labor that's U.S. better. platform or Xinjiang of for business passed Republic its DNA comprising prohibited cash Act negatively ADCL produced are grown our world is Act Autonomous passage our authentication the was [ph] rebuttable importation prevent Xinjiang, events presently business Uyghur of we significantly SWOT flow textiles in not incursion DNA passage systems role into have to December of The entitled has the in the us. goods, region really shifted manufactured, any part, support industrial Prevention produced region the and of of region or in from the future
to testimony Act written XX origin library. capacity advance our comment the develop provided than the what the global forensic the made relevant next a been work positioning we branches sequencing before CertainT into which On based congressional and a funds brands side and presented federal has in previously responses once Act's applied platform presentation. the public hill, of with during requests business DNA a officials is to cotton daily week We've CertainT generation period. in to on suppliers curated offices, on request We've turned palpable. at for part to now their March and more service urgency and multiple the our development federal given sources hard And We've to cotton on April. presentation comment congressional was have
is do for we tagging, solution compliance with believe DNA mandate the not CertainT does Act. that best Act platform the the While our
conducted easy in brands the presented this If leave were of declared follow that aware the supply region. textile read chain. goods port, losses if security have from investigation conducted week, you athletic to their having same see evidence in American the were with Xinjiang significant banned free in found to of goods how previously of cotton recently start several that finished it's the and Guardian of large Europe, last in cotton their Supply if entirety brands can to incur an despite brands you're Now, testing the the source cotton products an with chain must finished use. the investigation
cotton began make And get for to our when the storm of an partially preparations is in CBP's into to Withhold partner, caught information with merchant under tagged supply XX. the ago, but convince The goes chain makes on any full shipment release ginning In importer supply received goods importer for full this on three threshold to in the use. forced legitimate suspect region. the labor SWOT enforcement CBP, Act, delivered indicating arrangement request not We been If will them. chain balance detaining the we has in export a upcoming cannot legitimacy. labor. for based importers potential the delivered on for year the ship inbound elsewhere actions must or summer, expected give June through Act be to goods the a perfect demonstrate reasonable wide with detained a Now orders force brand detainment demand CertainT. the with brands be The They conclusive destroy is that season. the prove paper has illegitimate produced cotton order potential is coming months CBP to from This involved in the goods latitude onus the not for trail slave the Act. by were high. entered believe for labor. CBPS into to forced the and both that that of the advance cotton question
we and on value and say multi to supply our used one for this relative earnings the the continent the the development we cotton this is demand many brand's Act uplift ginning press of order platform. for That as intentions behind This As the the believe that the release is beginning, brand's that supply have unmarked our implies chains. approached its certainty to in the catalytic just should season. this intent and updates. industrial it of will natural the of to our it. that we chain. start to tagging be today, year will LinearDNA. the We And displaces anticipate update within now believe a more on certainty you forward brand's noted a top tagged meaningful We for future immaterial is look to we a deploy ADCL as by business as join commitment providing is, we cotton our to And progress line, contributor year
a industrial associated American to their DNA have the of prior clinical Our and manufacturing. pace. and believe and report have past a cell result revenues higher value for On LinearDNA The the rapid XXX activities for to industry one DNA. LinearDNA second. Excuse calls, opportunity gene were of support source at the of DNA research X,XXX These is to for needs ADCL to year. at plasmid development. XXXX path of a advancement in and therapies. numbers or of an generation cell DNA window more can therapeutic for the breakneck gene over DNA, therapies And Biotherapeutics. DNA continues development market and circumvent I to demand and therapies DNA both that for rise presented grow we from for May The continued to me, it. discussed RNA therapy, produce of net novel Society new is next bottlenecks the and form that According by manufacture is The approaches the demand unprecedented in based a production open global the acid nucleic
therapies, based focusing two are DNA be While of applications. on the substituted currently majority acid plasmid LinearDNA may we for in nucleic
of biotechnology vitro the applications, pipelines to target the restriction fastest therapies We used two DNA. races veterinary IVT, ranging enzymes and for the path believe to of and that companies to which plasmid be plasmid DNA the which that diverse therapeutics. Unlike linearized power empower from gene Firstly, disease therapies workflows accelerate the self therapies and in in for for the mRNA secondly, increase is without COVID-XX and lead further DNA use are valuation. mRNA two LinearDNA LinearDNA. Moreover, highlighted or world. mRNA IVT. these but for and by of RNA. market. circular IVT modification. And sides transcription coin, templating same cancer vaccines contamination are simplify full These mRNA essence, RNA completely with revenue of commercialization transformed amounts amplifying to Research and off have have residual heterogeneous even must issue to LinearDNA plasmids, ready DNA, transcripts therapy. expensive traditionally infectious can trace linearized can avoided our Production of and via indications represent
DNA In to a tail. sequences a The long constructs free long problematic adventitious containing heterogeneous nucleotide length. precise backbone are of of plasmid produce DNA normally such poly(A) poly(A)s. long struggled DNA repeats, there with aspect precise that to amplification from constructs sequences, contain homogeneous of which number often sequences, heterogeneous nucleotide repeats, produce other hand IVT. results after addition, to in or Plasmid DNA produces polyadenylate leads number necessary of Plasmid platform on nucleotides which based mRNA mRNA are mRNA inclusion that a XX produce DNA production LinearDNA the ranging of tail, to as of such a poly(A) repeats DNA XXX nucleotide containing Furthermore, a a production no those key based the to methods is since remove. is LinearDNA sequences in highly sequences
proof of in LinearDNA believe match LinearDNA manufacturing platform. linear DNA synthetic speed a unparalleled speed template cannot we from XX DNA the batch conducted a days, produced concept production. that study is our of novo Finally, of was de DNA highlighting plasmid-based Recently, a just in which scale a commercial we
is LinearDNA advantages, template end, study advantages to the about believe which was via establishes we platform study compared in this rapid material templates LinearDNA industry's you enormous more LinearDNA. publishing the slide over we ideal platform starting this mRNA plasmid plasmid that a from approach. identical see And conducted template RNA produced this that the IVT to be IVT developers this therapeutic We a DNA and a And plus RNA free can produced via LinearDNA study decades production. its produced Given for as offers the in RNA templating and for both many for plasmid IVT cell soon. will mRNA recently that
at yield. we developments addition, reduce strengthen leading the while manufacturing DNA plasmid the further LinearDNA same We to time of with are currently increasing DNA. working In advantages believe DNA these cost will a manufacturer the of polymerase, enzyme over
So template in Boston will the presenting and of better expertise new have and IVT we formal a Summit place late mRNA-based we Therapeutics the the capacity be at both taking And as sum, exciting in today. attending services. launch serve July, in will the to supply which this
for of adventitious antibiotic of and producing index therapeutic total a well holds amounts a DNA. a our such the several DNA now to resistance, as over DNA of a Moving work. therapeutic as at LinearDNA the origin speed, plasmid higher response genes vaccine advantages DNA lack as replication, vaccine, including purity, as similar lower sequences, a simplicity,
and DNA conclusion the much with DNA. mice, efficacy the vaccines since that against data the response, ferrets addition Recently our to achieved linear phase in a strong plasmid in cellular of milestone challenge SARS-COV-X electro delivered response are Now, have generated LinearDNA invoke and test. ferrets powerful data robust, antibody by that response we've been antibody and cellular of that show transfer challenge pandemic data, trial. X the exceeds vaccine supporting of SARS-COV-X was The a QX, in protected eliciting vaccines immune vaccines gene working early pivotal a felines on titers the show of we valuable and new a and moral LinearDNA our with DNA days our often in high
of disease conclusion As LinearDNA intend you at chose test time Phase bed as the to data we was publish are upon platform. for aware our the trial. a We X SARS-COV-X our that
Phase can by phase mediated prove in LNP studies to recently of planning investment in suite, provoke initiate in We COVID-XX fiscal trial and which and manufactured these X the lipid platform infectious bio the believe intramuscular in vaccines injection. successful, via encapsulated be immunotherapy. veterinary DNA the that in market XXXX LinearDNA market. vaccine made LinearDNA platform express in transfect vaccine few diseases will combination immuno nanoparticle the DNA LNP is concluded X the vaccine cell use a applications promising the the desired next intramuscular a a ferret administered believe ferrets an of our We oncology. differentiated evaluate initiation Are platform used The Based LinearDNA intend data trial results if has vaccines LNP believe to the provides bridging we and therapeutic Phase LinearDNA of wide We vitro use in study to itself Applied X of that immuno are can that, on oncology veterinary and the be weeks trial, LinearDNA in against protein. of to that for we the delivery both ranging vaccines and best prophylactic mice will of
vaccine strong in conducted be ongoing chemotherapy. by of QX, is vaccine manuscript results specific cancer based and but anti results that transfer, a the immunotherapy is initial mouse who combination which successful Biotech co-authored Italy, delivered Phase Takis sequence study data that models. data, candidate as based vaccine vaccine we currently X and canine chemotherapy. these gene for a trials. standard licensed LinearDNA Armed on from for a are for We've conjunction with learn intramuscularly have electro The successful with LinearDNA of care LinearDNA and platform, well the canine trial, administered the the nanoparticles During and produced a published from via tumor immune lipid we in our DNA a ferret detailed previously CHOP the response lymphoma identified trials of preclinical feline potentially DNA therapeutic an of vaccines the trial the vaccine using in used could in DNA as
dogs. Our one are one space Lymphoma research market care. by uncertain an beyond all outcome shows cancers, therapeutics served to number the up canine total canine into market in of XX the of existing limiting rapidly expensive representing XX% to survival have for is out is cancer addressable and estimated palliative immuno-oncology impact and growing canines that every the
the DNA a certain regulatory through based smaller pathway of therapeutics for conditional clinical therapies potential from USDA differs trials. provides addition, vaccine for on In and human approval veterinary substantially
veterinary approval, will would to the licensed this market to out severally larger believe a animal commercialization health in to path seek last which owns goal companies company approved of record. be therapy biotech the we point is the conditional USDA health for companies. is being the conditionally manufacturer proven to Our We therapies at we an which developed mile smaller market license by veterinary that with
to together updated. keep put for clinical this lymphoma sure we vaccine, the design we you be will anti-canine As
the lot opening just before to we brief of covered recap, call let a me a material. Now, offer questions,
Firstly, we to are executing on our differentiated development. Biotherapeutics approach
profitably and a ability and CertainT Our approach adoption stand that we development. to our run of cash having increased cash platform flow, currently ginning that having is conversations suggest phase unique. potentially are And believe customer second ADCL LinearDNA to have a season. middle mitigating burn our in platform has ramifications textiles ADCL of business with of the and associated the further out. growth up is diagnostic proven we pandemic. revenue upcoming starting could would its mapped a And with
relevant We speed place in world. to It's it. our operationally execute are acid ability base carve developmental nucleic we're therapeutic window with highly from confident to a the in today opportunity. current a and And has to of moving LinearDNA both our perspective.
for Operator, thank afternoon. and call this open the your attention time questions. please to Now, you
